BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11481387)

  • 1. Pathologic features of prostate cancer found at population-based screening with a four-year interval.
    Hoedemaeker RF; van der Kwast TH; Boer R; de Koning HJ; Roobol M; Vis AN; Schröder FH
    J Natl Cancer Inst; 2001 Aug; 93(15):1153-8. PubMed ID: 11481387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R; Roobol M; Schröder FH; van der Kwast TH
    Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).
    Roobol MJ; Kirkels WJ; Schröder FH
    BJU Int; 2003 Dec; 92 Suppl 2():48-54. PubMed ID: 14983955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH; Postma R; Hoedemaeker RF; van Leenders GJ; Schröder FH
    Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
    van der Cruijsen-Koeter IW; van der Kwast TH; Schröder FH
    J Natl Cancer Inst; 2003 Oct; 95(19):1462-6. PubMed ID: 14519752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Aus G; Damber JE; Khatami A; Lilja H; Stranne J; Hugosson J
    Arch Intern Med; 2005 Sep; 165(16):1857-61. PubMed ID: 16157829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
    Draisma G; Postma R; Schröder FH; van der Kwast TH; de Koning HJ
    Int J Cancer; 2006 Nov; 119(10):2366-71. PubMed ID: 16858675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.